'Do you need to do surgery?' Oncologist see a potential milestone in breast-cancer treatment
When Sabrina Jones was diagnosed with aggressive breast cancer, she expected to have surgery to remove the tumor—and her entire breast.But the 52-year-old manager at an educational-tech company responded so well to chemotherapy, her surgeon at the University of Texas.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
US Aid Cuts Are Making It Harder For Palestinian Women To Treat Their Breast CancerMore than 1,000 women who had mammograms done through a US-funded program and were flagged for follow-ups have had to seek other treatment options.
Baca lebih lajut »
Roche's Tecentriq wins U.S. approval for aggressive breast cancerRoche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign...
Baca lebih lajut »
FDA approves first immunotherapy regimen for breast cancerThe US Food and Drug Administration granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday. The drug, Genentech's Tecentriq, was approved for use in combination with Abraxane chemotherapy for patients who have a type of advanced triple negative breast cancer.
Baca lebih lajut »
Roche's Tecentriq notches win in breast cancer with U.S. approvalRoche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign...
Baca lebih lajut »
Fast-Growth Chickens Produce New Industry Woe: ‘Spaghetti Meat’The poultry industry faces product problems arising from birds bred for fast growth: Texture so squishy it’s called “spaghetti meat,” or so leathery it's called 'woody breast'
Baca lebih lajut »
US Aid Cuts Are Making It Harder For Palestinian Women To Treat Their Breast CancerMore than 1,000 women who had mammograms done through a US-funded program and were flagged for follow-ups have had to seek other treatment options.
Baca lebih lajut »
Roche's Tecentriq wins U.S. approval for aggressive breast cancerRoche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign...
Baca lebih lajut »
FDA approves first immunotherapy regimen for breast cancerThe US Food and Drug Administration granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday. The drug, Genentech's Tecentriq, was approved for use in combination with Abraxane chemotherapy for patients who have a type of advanced triple negative breast cancer.
Baca lebih lajut »